Peptide education
IGF-1 LR3
Long R3 IGF-1
IGF-1 LR3 is plain IGF-1 with two deliberate edits: an arginine swapped in at position 3 and a 13-amino-acid extension added to the front. Both edits do the same job, stopping IGF binding proteins from sequestering the molecule so more of it stays free to activate the IGF-1 receptor. That is the entire basis of its bodybuilding reputation, and also the entire problem: the modification that makes LR3 interesting is the one no human study has tested. Every human result people quote in this conversation, from the mecasermin label to pediatric rhIGF-1 trials to tendon research, belongs to a different molecule.
LR3 has never been given to a human in a controlled trial, full stop. Everything the market says it does is borrowed from an approved drug that is not LR3, from animals, or from receptor biology.
Overview
Quick answer
IGF-1 LR3 is not mecasermin, Increlex, or generic "IGF-1" physiology. Mecasermin is the approved pediatric replacement-drug comparator; LR3 is mainly visible through molecular papers, animal studies, comparator IGF-1 evidence, clinic and vendor pages, forum reports, and product-quality warnings.
What is IGF-1 LR3?
Long [Arg3]-IGF-I: native IGF-1 with an Arg-for-Glu substitution at position 3 plus a 13-amino-acid N-terminal extension. The edits cut binding to IGF binding proteins, leaving more free analogue to hit IGF-1 receptors in lab systems. That is a pharmacology statement, not a muscle-growth result.
What do people use it for or talk about?
Lean muscle, recovery, recomposition, fat loss, nutrient partitioning, site-specific growth, hyperplasia, anti-aging, cognition, and stacks with growth-hormone compounds: the clinic and forum list is long. What those sources cannot show is a measured LR3 outcome in an adult, because no controlled human LR3 trial exists.
What comparator and real-world patterns are reported?
The concrete numbers here belong to neighbors: mecasermin's pediatric label, long-term rhIGF-1 treatment, and animal LR3 infusions. Community LR3 practice sits around 20 to 50 mcg a day, often split bilaterally after training, in 4 to 6 week runs, with 100 mcg days flagged as aggressive even by users. That is reported practice, not a studied regimen, and no human LR3 dosing evidence exists to check it against.
What are the main practical risks?
Hypoglycemia leads, because IGF signaling lowers blood sugar and the closest human comparator, long-term pediatric rhIGF-1, reported hypoglycemia in 49% of treated children. Behind it: growth signaling you cannot aim, tumor-biology questions no LR3 study answers, and gray-market vials whose contents have already failed analytical testing, including one containing His-tagged Long-R3.
Why do public claims exceed the evidence?
Because the mechanism is real and easy to retell. IGF-1 receptor signaling does drive growth biology, so sellers borrow mecasermin's data, animal LR3 work, and generic IGF physiology and let the reader assume the vial inherits all of it. The gap between a plausible pathway and what a gray-market vial does to a physique is exactly where the evidence runs out.
Reported practice
Commonly reported protocol
Community performance protocols. Community-reported patterns, not verified by controlled human trials and not a use recommendation. Full use-pattern detail
Evidence
Evidence snapshot
Primary molecular papers describe the identity of Long [Arg3]-IGF-I and the reason it behaves differently from native IGF-1.
The cited registry and literature sources identify mecasermin and rhIGF-I comparators, not controlled LR3 human trials for muscle, recovery, or performance.
LR3 binds IGF-binding proteins far less strongly than native IGF-I and is tied to IGF1R signaling pathways such as PI3K and MAPK. That supports biological plausibility, not clinical outcome claims.
Clinic, vendor, and community sources discuss LR3 around bodybuilding and wellness goals, including lean mass, fat loss, site-specific growth, repair, anti-aging, cognition, and stacking.
Legitimate LR3 suppliers describe cell-culture use and broad release testing, while gray-market pages may use research-only disclaimers and COA language. A posted certificate may list a purity result for a submitted sample, but the unanswered questions are sequence identity, sterility, endotoxin, biological activity, storage history, and whether the shipped vial matches the tested lot.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Anecdotal evidence | Verdict |
|---|---|---|---|---|
| IGF-1 LR3 is clinically established for muscle growth. | No direct interventional human LR3 trial for muscle growth, strength, body composition, or performance was found. The human clinical data most often adjacent to this pathway involve mecasermin or rhIGF-I, not LR3. | IGF1R signaling is involved in growth biology, and LR3 has lower binding-protein affinity than native IGF-I. Animal studies show biological activity, but not a clean adult-human physique outcome. | Bodybuilding and gray-market discussions commonly present LR3 as an anabolic or recovery peptide, but those reports lack effect size, safety follow-up, and product identity. | Overstated. The support is mostly mechanism and market interest, not a direct human muscle-building result for LR3. |
| LR3 is just a longer-lasting version of IGF-1. | No direct human LR3 pharmacokinetic study is available. The comparator evidence does not answer the LR3 pharmacokinetic question. | Primary comparative work supports lower IGF-binding-protein affinity and higher apparent potency in some systems, but also reported faster plasma disappearance than native IGF-I in animal work. Binding behavior, receptor potency, and blood clearance describe different parts of the pharmacology. | Vendor and community pages often turn this into claims that LR3 stays active for 20 to 30 hours. That sounds more settled than the primary evidence allows. | Too simple. LR3 is meaningfully different from native IGF-I, but the common long-half-life claim compresses several different pharmacology questions into one marketing line. |
| LR3 helps recovery, tendons, repair, or injuries. | Human connective-tissue work with IGF-I exposures supports interest in collagen and tendon biology. It still does not answer the LR3-specific question: whether LR3, especially from a gray-market vial, changes injury recovery in people. | IGF-axis signaling can affect tissue growth and collagen-related biology. That is plausible background for repair language, but the LR3 evidence here is mainly molecular, animal, and comparator material. | Clinics, vendors, and forums discuss recovery, repair, and stacking with growth-hormone-supporting compounds. Those reports describe goals and routines, not measured repair outcomes. | Plausible biology, but direct human repair outcomes for tendons, joints, and injuries were not found in the cited LR3 material. |
| LR3 supports fat loss, recomp, nutrient partitioning, or anti-aging. | Direct human LR3 trials for these public claims were not found. rhIGF-I metabolic studies can inform risk and mechanism, but they do not answer body-recomposition or anti-aging outcomes for LR3. | IGF and insulin-related signaling can affect glucose disposal and growth pathways. That biology can cut both ways, because hypoglycemia and growth signals are part of the same safety conversation. | Clinic and wellness pages discuss fat loss, recomposition, cognition, anti-aging, and skin-related claims. That language is mostly marketing. | Mostly extrapolation from mechanism and market positioning. The evidence explains why these claims exist, but it does not show that LR3 produces those benefits in people. |
| A vendor COA makes an LR3 vial equivalent to a regulated product. | No human trial source shows that current vendor vials match an approved product, trial-grade material, or a release-tested research reagent. | LR3 identity depends on sequence, structure, biological activity, endotoxin, bioburden, handling, and adsorption behavior. A simple purity screenshot leaves most of those product questions unanswered. | Vendor pages may advertise third-party COAs while also labeling the product research-only and outside the 503A or 503B pharmacy framework. | A COA may describe a submitted batch. The practical risk is the vial in hand: whether it is sterile, potency-accurate, sequence-confirmed, and suitable for injection needs separate proof. |
Bottom line
Main takeaway
IGF-1 LR3 is a modified growth factor with a loud bodybuilding reputation and zero direct human trials behind it. The edit that makes it popular is the same edit that leaves it unstudied.
Keep four evidence piles separate: mecasermin labels, native IGF-1 physiology, animal LR3 studies, and vendor claims. Only the animal pile is actually about LR3, and none of the piles measures what a gray-market vial does in an adult.
LR3-specific literature is molecular and preclinical. The human data are mecasermin and rhIGF-1 comparators, most useful for sizing the hypoglycemia and growth-signal risks that LR3 would inherit if it behaves like its parent.
Identity
What it is
IGF-1 LR3 is Long [Arg3]-IGF-I: the 70-amino-acid IGF-1 molecule with an Arg-for-Glu change at position 3 and 13 extra amino acids on the N-terminus. Both modifications reduce binding to the IGF binding proteins that normally control how much free IGF-1 reaches its receptor.
The one thing everyone repeats about LR3, that it stays active for 20 to 30 hours, is not as settled as the repetition suggests. No human pharmacokinetic study exists, and the primary comparative work in animals reported faster plasma disappearance than native IGF-1, alongside higher apparent potency in some systems. Binding behavior, receptor potency, and blood clearance are three different questions, and the marketing line compresses them into one.
The approved drug in this neighborhood is mecasermin, recombinant human IGF-1 for severe pediatric deficiency. It is the unmodified molecule, its evidence cannot be transferred to LR3, and the animal LR3 work itself complicates the muscle story: in a rat food-restriction study, LR3 moved body-weight outcomes without cleanly preserving skeletal muscle.
The market splits in two. Legitimate suppliers sell LR3 as a cell-culture reagent with release testing, explicitly not for human use; gray-market vendors sell vials with COAs and benefit copy. Published testing of black-market IGF products has already found a vial containing His-tagged Long-R3-IGF-I, which is the identity problem in concrete form.
How people talk about it online
Bodybuilding forums treat LR3 as the long-acting IGF option: post-training bilateral injections, pumps, nutrient partitioning, and stacks with GH secretagogues, with the 20 to 30 hour half-life repeated as settled fact. The WADA prohibition on growth factors gets mentioned less often than the cycles.
Clinic and wellness pages run wider than the forums: repair, anti-aging, cognition, skin, and fat loss. The further the claim from the receptor biology, the thinner the support, and it was thin at the start.
Vendor pages pair research-only disclaimers with COAs and outcome-flavored copy. A certificate describes a submitted sample; it does not establish that the vial in hand is sequence-correct, sterile, or potent.
Use context
Routes, doses, and cycle patterns
No controlled human LR3 protocol was found for physique, recovery, or anti-aging use. The route and amount details come from mecasermin labeling, long-term rhIGF-I pediatric treatment, animal LR3 studies, and market pages that describe research-only or gray-market injectable vials without giving a clinical schedule.
Human studies and product labels
Mecasermin label comparator
- Purpose
- Severe primary IGF-1 deficiency in pediatric patients
- Context
- FDA label and comparator human product
- Route
- Subcutaneous
- Amount
- 0.04 to 0.08 mg/kg starting dose, up to 0.12 mg/kg
- Frequency
- Twice daily
- Duration
- Long-term treatment under labeled pediatric context
These numbers belong to mecasermin, not LR3. They help show the approved comparator and its safety concerns, especially hypoglycemia, but they are not LR3 use instructions.
Long-term pediatric rhIGF-I treatment
- Purpose
- Severe growth-hormone insensitivity or severe primary IGF-1 deficiency
- Context
- Long-term human comparator study
- Route
- Subcutaneous
- Amount
- 60 to 120 micrograms/kg
- Frequency
- Twice daily
- Duration
- Long-term pediatric treatment
This study gives class-relevant human adverse-event context, including hypoglycemia, lipohypertrophy, and tonsillar or adenoidal hypertrophy. It cannot show LR3 performance benefit.
Rat food-restriction LR3 study
- Purpose
- Preclinical growth and tissue effects
- Context
- Animal study
- Route
- Continuous infusion
- Amount
- 98 nmol/day/kg
- Frequency
- Continuous
- Duration
- 7 days
The animal study complicates the muscle-gain claim: LR3 changed body-weight-related outcomes without cleanly preserving skeletal muscle.
Fetal sheep LR3 infusion
- Purpose
- Organ growth and nutrient-handling biology
- Context
- Animal study
- Route
- Intravenous infusion
- Amount
- No public amount in the study summary
- Frequency
- Continuous infusion
- Duration
- One week
This supports broad growth-factor activity and altered nutrient handling in a preclinical setting, not adult human bodybuilding dosing.
Human connective-tissue IGF-I exposure
- Purpose
- Tendon and collagen biology
- Context
- Human mechanistic comparator study
- Route
- Local administration around tendon tissue
- Amount
- No public amount in the study summary
- Frequency
- No public schedule in the study summary
- Duration
- Tissue sampling after local exposure
This helps explain why repair language is mechanistically plausible, but it is not a whole-body LR3 recovery or hypertrophy trial.
Real-world discussion
Community performance protocols
- Purpose
- Muscle growth and recovery discussion
- Context
- Forums, vendors, and protocol blogs
- Route
- Subcutaneous injection
- Amount
- Community schedules typically describe 20 to 50 mcg per day, often split bilaterally after training; some reports describe up to 100 mcg per day, which community sources themselves flag as aggressive.
- Frequency
- Once daily, often post-training, in most descriptions
- Duration
- Usually described as short cycles of 4 to 6 weeks because of receptor-downregulation concerns
IGF-1 LR3 is a potent modified IGF-1 with real hypoglycemia risk, and the long-acting modification that makes it popular is exactly what distinguishes it from the approved plain-IGF-1 drug. This is reported practice, not a recommendation.
What varies
- Identity: LR3, mecasermin, native IGF-1, and generic IGF-axis discussion differ in molecule, indication, duration of exposure, and safety data.
- Route: the market usually implies injection, while legitimate LR3 supplier language may describe cell-culture or research-reagent use.
- Amount: the concrete human amounts here belong to mecasermin or rhIGF-I comparators, so they cannot be converted into LR3 performance dosing.
- Source type matters: a trial can measure outcomes, an animal study can suggest biology, a clinic page can show sales positioning, a vendor listing can show product claims, and a forum post can show personal-use patterns.
- Product quality: sequence identity, activity, sterility, endotoxin, concentration, adsorption, storage, and shipping conditions all matter.
Human data
Human evidence
There is no direct human LR3 evidence: no interventional trial, no pharmacokinetic study, no safety program, in any population. What exists in humans belongs to neighbors, meaning mecasermin's approved pediatric label, long-term rhIGF-1 treatment with its substantial hypoglycemia and tissue-growth adverse events, and mechanistic IGF-1 work in tendon and metabolism. Those sources calibrate the risks of pushing the IGF axis, but none of them measures what LR3 does to muscle, fat, recovery, cognition, or aging in adults. The physique reputation rests on mechanism, animal studies, and repetition.
Evidence maturity
IGF-1 LR3's popularity comes entirely from a modification that has never been studied in humans.
Plain IGF-1 (mecasermin) is an approved drug for severe primary deficiency.
LR3 changes reduce binding-protein attachment; the long-half-life line is vendor repetition, not a measured result.
None for the LR3 form; mechanism risk (hypoglycemia) is the dominant fact.
Explicitly prohibited under WADA growth-factor rules.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Direct IGF-1 LR3 human evidence | No LR3-treated human cohort found | Comparator evidence summary | No approved LR3 product found | The cited human material involves mecasermin and rhIGF-I, not LR3-named human intervention studies. | Mecasermin labels, native IGF-1 physiology, and vendor claims should not be treated as direct LR3 human evidence. | weak |
| Mecasermin label and regulatory comparator | Pediatric patients with severe primary IGF-1 deficiency or related labeled contexts | FDA label and official comparator documentation | Approved recombinant human IGF-1 product, not LR3 | Mecasermin has labeled pediatric growth-failure use and substantial safety language, including hypoglycemia and growth-related warnings. | It is a different molecule and indication. It is relevant as a comparator, but it does not show that LR3 works for adult muscle or body composition. | moderate |
| Long-term rhIGF-I pediatric treatment | Children with severe growth-hormone insensitivity or severe primary IGF-1 deficiency | Long-term human treatment study | rhIGF-I comparator | The study reported growth-related treatment experience and adverse events, including hypoglycemia in 49%, lipohypertrophy in 32%, and tonsillar or adenoidal hypertrophy in 22%. | Pediatric therapeutic dosing and safety experience cannot map a dose, benefit, or risk profile for adult gray-market performance use of LR3. | moderate |
| Human IGF-I tendon and metabolic mechanism work | Healthy adults or human tissue-focused IGF-I exposure settings | Human mechanistic comparator studies and reviews | rhIGF-I or IGF-axis comparator | Human IGF-axis studies show effects on collagen, tendon, and metabolic biology, which explains why recovery and nutrient-partitioning claims keep showing up. | Mechanistic comparator work explains why that marketing appears; it leaves LR3 body composition, strength, and anti-aging outcomes unmeasured. | weak |
Cautions
Safety and unknowns
- Hypoglycemia is the first class-relevant safety issue to notice. Mecasermin labeling and rhIGF-I human data show that IGF-axis treatment can produce clinically important low blood sugar, including severe events.
- Comparator labeling also raises intracranial hypertension, lymphoid tissue hypertrophy, slipped capital femoral epiphysis, scoliosis progression, hypersensitivity, and malignant-neoplasia warnings.
- LR3-specific long-term human safety, immunogenicity, cancer-related risk, and dose-response data are missing.
- Animal studies show broader growth-factor biology, including organ and nutrient-handling effects, which does not match a narrow "muscle only" market claim.
- Gray-market use adds identity, sterility, endotoxin, concentration, sequence, storage, reconstitution, and shipping uncertainty on top of the biological uncertainties.
Product quality
A vial label is only a starting point
Legitimate LR3 supplier material describes cell-culture or research-reagent use, not human application, and includes release testing such as identity, purity, biological activity, bioburden, and endotoxin.
A vendor-posted COA can be helpful for documenting a stated batch result. Injectable quality also depends on sterility, representative lot sampling, potency accuracy, and sequence-correct LR3 for the product being used.
Published analytic work has found black-market IGF-related products with unexpected composition, including an injectable vial containing His-tagged Long-R3-IGF-I.
Identity
LR3 is a specific analogue. A label that says IGF-1, LR3, myostatin, growth factor, or research peptide cannot show the vial contains the intended molecule.
Sequence and tag status
The black-market finding of His-tagged Long-R3-IGF-I shows why sequence variants and process-related tags are practical concerns.
Sterility and endotoxin
Injectable interest makes bioburden and endotoxin controls central. Purity percentages still need sterility, endotoxin, and representative-lot evidence.
Concentration and dose math
Even when a vial contains LR3, concentration accuracy, reconstitution, adsorption to surfaces, storage, and shipping can change what a person actually receives.
COA reliability
FDA GMP guidance and peptide-quality literature both support checking supplier certificates rather than accepting them at face value.
Mechanism
How it is proposed to work
IGF-1 LR3 is built to escape some of the binding-protein control that shapes native IGF-1 exposure. That can increase apparent activity in some models, but it also makes the biology less like a simple replacement for native IGF-1.
The central design feature is much lower affinity for several IGF-binding-protein settings, which can leave more analogue available to interact with IGF1R in model systems.
IGF1R signaling connects to PI3K and MAPK pathways involved in growth, metabolism, and tissue remodeling. Those pathways make anabolic claims biologically plausible, but they do not show adult human outcomes.
Animal work complicates the market claim: LR3-related studies report organ-specific growth, altered amino-acid and insulin profiles, and cases where body-weight effects were clearer than skeletal-muscle preservation.
Both modifications reduce binding to IGF binding proteins, leaving more free ligand for IGF-1-receptor and AKT-pathway signaling: the same change behind the apparent potency in models and the hypoglycemia potential.
FAQ
Common questions
Is IGF-1 LR3 the same as IGF-1?
No. The approved drug mecasermin is plain IGF-1 for severe primary deficiency. LR3 is a modified analog with an extended half-life, and that modification has no human clinical literature at all.
How are people using it in practice?
Community protocols commonly describe 20 to 50 mcg per day, often split bilaterally after training, in short 4 to 6 week cycles.
Details
Technical details
Sources
References
- 1.
LR3 identity papers. Francis 1992 and Flint 1994 on Long IGF-I and R3-modified analogues.
Core identity, naming, and structural architecture of Long [Arg3]-IGF-I.
- 2.
LR3 animal studies. Tomas 2001, Conlon 1995, and Stremming 2021 preclinical outcome papers.
Animal outcomes, organ-growth signals, and the mismatch with selective-muscle narratives.
- 3.
Increlex comparator label. FDA Increlex label, Purple Book, and EMA Increlex documentation.
Approved comparator status, indication, contraindications, and warnings.
- 4.
Pediatric rhIGF-I trial. Long-term rhIGF-I pediatric trial in severe GH insensitivity.
Comparator human outcomes and adverse-event frequencies.
- 5.
LR3 human-trial search. Targeted ClinicalTrials.gov and literature review for IGF-1 LR3 human intervention studies.
Documents that comparator sources were found, but no LR3-treated interventional human cohort was identified.
- 6.
FTC claim guidance. FTC Health Products Compliance Guidance.
Health-claim substantiation standard.
- 7.
Elite Edge vendor page. Elite Edge Biotech IGF-1 LR3 vendor page.
Research-only sales pattern, COA language, and non-503A or non-503B status claim.
- 8.
Clinic and forum claims. Clinic, vendor, and community claim examples including Vida, Anderson, and site-specific or hyperplasia narratives.
Gray-market demand signals and excluded-claim capture.
- 9.
FDA seller warnings. FDA warning letters, Kimergård 2014, and recent peptide-market studies.
Public-health context, online peptide enforcement, and market expansion risk.
- 10.
COA quality guidance. FDA Q7A and peptide COA discrepancy literature.
Why a posted COA is only one part of regulated-quality material.
- 11.
Malignancy context. NCI cancer resources, IGF-cancer reviews and pooled analyses, plus FDA malignant-neoplasia warning.
Malignancy-related uncertainty and why “safe growth factor” framing is indefensible.
- 12.
IGF tissue studies. Human rhIGF-I tendon and metabolic studies, plus IGF1R signaling and connective-tissue reviews.
Human comparator mechanistic evidence and pathway interpretation.